Orbis Biosciences has entered into an exclusive global license agreement leveraging its Precision Particle Fabrication technology. Reckitt Benckiser and Orbis have entered into an exclusive cooperation agreement to develop and commercialize novel technologies in the field of consumer healthcare. The technology will enable new products for a leading segment of RB's product portfolio. Detailed financial terms were not disclosed.
"We are proud to be partnering with one of the largest consumer products companies in the world to create differentiated products for their portfolio. The ability to add novel products to their extensive offering will provide patients the choice and flexibility they need to ease administration challenges," said Maria Flynn, CEO and President of Orbis Biosciences.